Compare Stocks: VANI, NVO, LLY, and VKTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$1,433.34 -0.3%	$1,236.58	$850.51 ▼ $1,460.00	$1.35T	0.4	3.07 million shs	2.40 million shs
NVO Novo Nordisk A/S	$40.66 -1.0%	$40.20	$35.12 ▼ $64.16	$183.47B	0.7	11.30 million shs	15.75 million shs
VANI Vivani Medical	$0.98 -13.0%	$1.19	$0.80 ▼ $1.66	$101.93M	2.51	192,462 shs	1.39 million shs
VKTX Viking Therapeutics	$27.58 -3.0%	$29.42	$23.82 ▼ $43.10	$3.63B	0.79	4.29 million shs	2.19 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	-0.29%	+4.71%	+22.82%	+21.24%	+40.76%
NVO Novo Nordisk A/S	-1.13%	+0.93%	+6.91%	-11.43%	-19.09%
VANI Vivani Medical	-12.97%	-5.44%	-16.66%	-29.76%	-35.73%
VKTX Viking Therapeutics	-3.02%	+6.94%	+3.49%	-16.90%	-32.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$1,433.34 -0.3%	$1,236.58	$850.51 ▼ $1,460.00	$1.35T	0.4	3.07 million shs	2.40 million shs
NVO Novo Nordisk A/S	$40.66 -1.0%	$40.20	$35.12 ▼ $64.16	$183.47B	0.7	11.30 million shs	15.75 million shs
VANI Vivani Medical	$0.98 -13.0%	$1.19	$0.80 ▼ $1.66	$101.93M	2.51	192,462 shs	1.39 million shs
VKTX Viking Therapeutics	$27.58 -3.0%	$29.42	$23.82 ▼ $43.10	$3.63B	0.79	4.29 million shs	2.19 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	-0.29%	+4.71%	+22.82%	+21.24%	+40.76%
NVO Novo Nordisk A/S	-1.13%	+0.93%	+6.91%	-11.43%	-19.09%
VANI Vivani Medical	-12.97%	-5.44%	-16.66%	-29.76%	-35.73%
VKTX Viking Therapeutics	-3.02%	+6.94%	+3.49%	-16.90%	-32.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,416.64	-1.17% Downside
NVO Novo Nordisk A/S	2.00	Hold	$59.44	46.17% Upside
VANI Vivani Medical	2.33	Hold	$3.75	281.33% Upside
VKTX Viking Therapeutics	2.79	Moderate Buy	$93.36	238.52% Upside

Current Analyst Ratings Breakdown

Latest VANI, NVO, LLY, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/12/2026	LLY Eli Lilly and Company	China Merchants Securities Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold
11/9/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$1,610.00 ➝ $1,700.00
11/2/2026	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$1,440.00 ➝ $1,600.00
10/30/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B+) ➝ Buy (B)
10/30/2026	LLY Eli Lilly and Company	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$1,300.00 ➝ $1,550.00
10/30/2026	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$1,425.00 ➝ $1,625.00
10/30/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$1,650.00
10/30/2026	LLY Eli Lilly and Company	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1,497.00
10/30/2026	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$1,330.00 ➝ $1,500.00
10/30/2026	LLY Eli Lilly and Company	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1,376.00 ➝ $1,612.00
10/30/2026	VKTX Viking Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$106.00 ➝ $118.00

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LLY Eli Lilly and Company	$65.18B	20.69	$25.07 per share	57.18	$42.81 per share	33.48
NVO Novo Nordisk A/S	$46.80B	3.88	$4.64 per share	8.77	$7.51 per share	5.41
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$4.62 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LLY Eli Lilly and Company	$20.64B	$30.81	46.52	28.27	1.72	31.90%	86.76%	22.03%	N/A
NVO Novo Nordisk A/S	$15.51B	$3.97	10.24	11.79	1.41	33.99%	53.52%	19.49%	N/A
VANI Vivani Medical	-$26.61M	-$0.35	N/A	N/A	N/A	N/A	-150.79%	-65.73%	N/A
VKTX Viking Therapeutics	-$359.64M	-$5.40	N/A	N/A	N/A	N/A	-117.35%	-88.87%	N/A

Latest VANI, NVO, LLY, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	VANI Vivani Medical	-$0.09	-$0.08	+$0.01	-$0.08	N/A	N/A
10/29/2026	Q3 2026	LLY Eli Lilly and Company	$5.71	$7.48	+$1.77	$7.22	$22.58 billion	$24.40 billion
10/28/2026	Q3 2026	VKTX Viking Therapeutics	-$1.06	-$1.55	-$0.49	-$1.55	N/A	N/A
8/13/2026	Q2 2026	VANI Vivani Medical	-$0.0833	-$0.07	+$0.0133	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LLY Eli Lilly and Company	$6.92	0.48%	+15.18%	22.46%	11 Years
NVO Novo Nordisk A/S	$0.82	2.02%	+21.74%	20.65%	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest VANI, NVO, LLY, and VKTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/26/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.48%	11/13/2026	11/13/2026	12/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LLY Eli Lilly and Company	1.17	1.39	1.00
NVO Novo Nordisk A/S	0.54	0.84	0.64
VANI Vivani Medical	N/A	3.25	3.25
VKTX Viking Therapeutics	0.43	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
VANI Vivani Medical	6.78%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
VANI Vivani Medical	53.30%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LLY Eli Lilly and Company	50,000	940.74 million	939.43 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
VANI Vivani Medical	36	90.20 million	42.13 million	Optionable
VKTX Viking Therapeutics	74	127.52 million	120.76 million	Optionable

VANI, NVO, LLY, and VKTX Headlines

Recent News About These Companies

Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028

2 hours ago | fool.com

Viking Therapeutics stock trades at EUR 25.68 on Thursday

November 12 at 11:03 AM | ad-hoc-news.deA

Is Viking Therapeutics (VKTX) Priced For Perfection After ObesityWeek?

November 12 at 6:02 AM | finance.yahoo.com

Viking Therapeutics (VKTX) Heads To Two Conferences, Is The Discount To Analyst Targets Warranted?

November 12 at 6:02 AM | finance.yahoo.com

Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?

November 11 at 5:34 PM | fool.com

Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55

November 11 at 5:00 PM | fxempire.comF

Viking Therapeutics stock trades at 26.00 euros Tuesday

November 10 at 10:01 AM | ad-hoc-news.deA

Novo Up 4% in a Month: How Should Investors Approach the Stock Now?

November 9, 2026 | zacks.com

Novo Up 4% in a Month: How Should Investors Approach the Stock Now?

November 9, 2026 | finance.yahoo.com

Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026

November 9, 2026 | finance.yahoo.com

Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026

November 9, 2026 | prnewswire.com

Can You Justify Buying Corcept Stock Today?

November 8, 2026 | trefis.comT

Here's the 1 Stock I'd Most Want to Buy If the Market Crashes

November 5, 2026 | fool.com

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

November 4, 2026 | fool.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2026 | finance.yahoo.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2026 | prnewswire.com

Viking Therapeutics (NASDAQ:VKTX) Stock Price Target Raised at Canaccord Genuity Group

November 2, 2026 | marketbeat.com

UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

November 2, 2026 | fool.com

HC Wainwright Issues Pessimistic Estimate for VKTX Earnings

November 2, 2026 | americanbankingnews.com

HC Wainwright Has Negative Estimate for VKTX FY2026 Earnings

November 2, 2026 | marketbeat.com

Viking Therapeutics Bets Big on VK2735 in Earnings Call

October 31, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VANI, NVO, LLY, and VKTX Company Descriptions

Eli Lilly and Company NYSE:LLY

$1,433.34 -3.95 (-0.27%)

Closing price 11/12/2026 03:59 PM Eastern

Extended Trading

$1,433.57 +0.23 (+0.02%)

As of 06:15 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$40.66 -0.43 (-1.04%)

Closing price 11/12/2026 03:59 PM Eastern

Extended Trading

$40.73 +0.07 (+0.16%)

As of 06:16 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Vivani Medical NASDAQ:VANI

$0.98 -0.15 (-12.97%)

Closing price 11/12/2026 04:00 PM Eastern

Extended Trading

$0.98 -0.01 (-0.85%)

As of 04:00 AM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Viking Therapeutics NASDAQ:VKTX

$27.58 -0.86 (-3.02%)

Closing price 11/12/2026 04:00 PM Eastern

Extended Trading

$27.90 +0.32 (+1.14%)

As of 06:13 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VANI, NVO, LLY, and VKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VANI, NVO, LLY, and VKTX Earnings

Compare Dividends

Latest VANI, NVO, LLY, and VKTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VANI, NVO, LLY, and VKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VANI, NVO, LLY, and VKTX Company Descriptions

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Vivani Medical NASDAQ:VANI

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools